![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca Invests in VaxEquity to Develop RNA-Based Technology
AstraZeneca Invests in VaxEquity to Develop RNA-Based Technology
![AstraZeneca](https://www.fdanews.com/ext/resources/test/Device_Images2/AstraZeneca.gif?t=1576126438&width=430)
AstraZeneca will invest in VaxEquity, a spin-off of Imperial College London, expanding its portfolio into self-amplifying RNA (saRNA) therapeutics.
The saRNA platform uses similar technology to messenger RNA but has self-amplifying abilities that enable proteins to be expressed for longer, delivering higher protein levels per dose.
The Anglo-Swedish drugmaker will provide VaxEquity with an undisclosed amount of research and development funding and up to $195 million in future milestones-based payments, in addition to royalties.
Under the deal, AstraZeneca has an option to collaborate with the company on up to 26 drug targets.
Upcoming Events
-
21Oct